Directorio de personas
Luis Brieva Ruiz

Luis Brieva Ruiz

Grado: Doctor

973 705 367
lbrieva.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3812-2011

Publicaciones

  • Munoz-Lopetegi, A; Pujol, M; Gimenez, M; Gaig, C; Brieva, L; Santamaria, J

    Abnormal sleep behavior caused by hypoglycemia

    SLEEP MEDICINE 85 268-270. .

    [doi:10.1016/j.sleep.2021.07.029]

  • Meca-Lallana J; García-Merino JA; Martínez-Yélamos S; Vidal-Jordana A; Costa L; Eichau S; Rovira À; Brieva L; Agüera E; Zarranz AR

    Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies.

    Neurodegenerative Disease Management 11 251-261. .

    [doi:10.2217/nmt-2020-0049]

  • Maurino J; Sotoca J; Sempere ÁP; Brieva L; López de Silanes C; Caminero AB; Terzaghi M; Gracia-Gil J; Saposnik G

    High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions.

    Patient-Patient Centered Outcomes Research 14 241-248. .

    [doi:10.1007/s40271-020-00454-3]

  • Fernandez-Velasco, JI; Kuhle, J; Monreal, E; Meca-Lallana, V; Meca-Lallana, J; Izquierdo, G; Gascon-Gimenez, F; de la Maza, SS; Walo-Delgado, PE; Maceski, A; Rodriguez-Martin, E; Roldan, E; Villarrubia, N; Saiz, A; Blanco, Y; Sanchez, P; Carreon-Guarnizo, E; Aladro, Y; Brieva, L; Iniguez, C; Gonzalez-Suarez, I; de Antonio, LAR; Masjuan, J; Costa-Frossard, L; Villar, LM

    Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

    Neurology-Neuroimmunology & Neuroinflammation 8 e940-. .

    [doi:10.1212/NXI.0000000000000940]

  • Otero-Romero S; Rodríguez-García J; Vilella A; Ara JR; Brieva L; Calles C; Carmona O; Casanova V; Costa-Frossard L; Eichau S; García-Merino JA; Garcia-Vidal C; González-Platas M; Llaneza M; Martínez-Ginés M; Meca-Lallana JE; Prieto JM; Rodríguez-Antigüedad A; Tintoré M; Blanco Y; Moral E; en nombre del Grupo de enfermedades desmielizantes de la SEN

    Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement.

    Neurologia (barcelona, Spain) 36 50-60. .

    [doi:10.1016/j.nrl.2020.02.006]

  • Meca-Lallana JE; Fernández-Prada M; García Vázquez E; Moreno Guillén S; Otero Romero S; Rus Hidalgo M; Villar Guimerans LM; Eichau Madueño S; Fernández Fernández Ó; Izquierdo Ayuso G; Álvarez Cermeño JC; Arnal García C; Arroyo González R; Brieva Ruiz L; Calles Hernández C; García Merino A; González Platas M; Hernández Pérez MÁ; Moral Torres E; Olascoaga Urtaza J; Oliva-Nacarino P; Oreja-Guevara C; Ortiz Castillo R; Oterino A; Prieto González JM; Ramió-Torrentá L; Rodríguez-Antigüedad A; Saiz A; Tintoré M; Montalbán Gairin X

    Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    NEUROLOGIA -. .

    [doi:10.1016/j.nrl.2019.11.003]

  • Meca-Lallana, J; Maurino, J; Hernández-Pérez MÁ; Sempere, AP; Brieva, L; García-Arcelay E; Terzaghi, M; Saposnik, G; Ballesteros, J

    Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing-Remitting Multiple Sclerosis: Quantifying the Patient's Perspective.

    Neurology and Therapy 9 173-179. .

    [doi:10.1007/s40120-020-00176-6]

  • Vazquez-Justes, D; Carreño-Gago L; Garcia-Arum, E; Traveset, A; Montoya, J; Ruiz-Pesini, E; Lopez, R; Brieva, L

    Mitochondrial m.13513G > A Point Mutation in ND5 in a 16-Year-Old Man with Leber Hereditary Optic Neuropathy Detected by Next-Generation Sequencing

    Journal of Pediatric Genetics 8 231-234. .

    [doi:10.1055/s-0039-1691812]

  • Gonzalo, H; Nogueras, L; Gil-Sanchez, A; Hervas, JV; Valcheva, P; Gonzalez-Mingot, C; Martin-Gari, M; Canudes, M; Peralta, S; Solana, MJ; Pamplona, R; Portero-Otin, M; Boada, J; Serrano JCE; Brieva, L

    Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis Patients

    Frontiers in Neuroscience 13 938-938. .

    [doi:10.3389/fnins.2019.00938]

  • Nogueras, L; Gonzalo, H; Jove, M; Sol, J; Gil-Sanchez, A; Hervas, JV; Valcheva, P; Gonzalez-Mingot, C; Solana, MJ; Peralta, S; Pamplona, R; Brieva, L

    Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis

    SCIENTIFIC REPORTS 9 11313-11313. .

    [doi:10.1038/s41598-019-47906-x]

  • Oreja-Guevara, C; Ayuso Blanco T; Brieva Ruiz L; Hernández Pérez MÁ; Meca-Lallana, V; Ramió-Torrentà L

    Cognitive Dysfunctions and Assessments in Multiple Sclerosis

    Frontiers in Neurology 10 581-581. .

    [doi:10.3389/fneur.2019.00581]

  • Fernandez, O; Tintore, M; Saiz, A; Calles-Hernandez, MC; Comabella, M; Ramio-Torrenta, L; Oterino, A; Izquierdo, G; Tellez, N; Garcia-Merino JA; Brieva, L; Arnal-Garcia, C; Aladro, Y; Mendibe-Bilbao, MD; Meca-Lallana, JE; Romero-Pinel, L; Martinez-Gines, ML; Arroyo, R; Oreja-Guevara, C; Costa-Frossard, L; Carrascal, P; Rodriguez-Antiguedad, A

    Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II)

    REVISTA DE NEUROLOGIA 68 468-479. .

    [doi:10.33588/rn.6811.2019121]

Proyectos

  • EMCOVID-19: Esclerosis Múltiple y COVID-19
  • Red esclerosis múltiple (REMM)
  • CONVENIS I CONTRACTES DR. LUIS BRIEVA
  • "Registro de pacientes con esclerosis múltiple (EM) tratados con Natalizumab en España"